Endometriosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Endometriosis, a condition characterized by the abnormal proliferation of endometrial tissue similar to that lining the uterus but occurring outside it, manifests as endometrial implants in ectopic sites. These lesions are commonly found on organs such as the ovaries, Fallopian tubes, uterine surface, bowel, and pelvic cavity membrane (peritoneum), with less frequent occurrences in the vaginal, cervical, and bladder regions. While occasionally found outside the pelvis, endometriosis generally remains confined to the pelvic area. Endometrial implants can lead to complications, but they typically pose no significant harm. The severity of endometriosis is classified into four stages—mild (Stage I), mild (Stage II), moderate (Stage III), and severe (Stage IV)—based on criteria including the number, location, and depth of implants and the presence of filmy or dense adhesions. Another staging system primarily assesses the severity of pelvic pain. However, a more reliable staging method is actively sought due to substantial intra- and inter-observer variability in these systems. The U.S. Food and Drug Administration (FDA) has approved several medications for managing endometriosis, including Lupron Depot (leuprolide acetate for depot suspension), Myfembree (relugolix, estradiol, and norethindrone acetate), Orilissa (elagolix), and Zoladex (goserelin acetate implant).
• Globally, endometriosis affects approximately 10% (190 million) of women and girls of reproductive age.

Thelansis’s “Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Endometriosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Endometriosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Endometriosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Endometriosis, Endometriosis market outlook, Endometriosis competitive landscape, Endometriosis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)